1 Proton Therapy for Atypical Meningiomas Mark W. Mcdonald
Proton therapy for atypical meningiomas of Neuro-Oncology, 123(1), 123–128. http://doi.org/10.1007/s11060-015-1770-9 McDonald, M. W., Plankenhorn, D. A., McMullen, K. P., Henderson, Dropcho, E. J., Shah, V., & Cohen-Gadol, A. (2015). Proton therapy for atypical meningiomas. Journal This is the author's manuscript of article published in final edited form as: Mark W. McDonald, M.D.,1,5 David A. Plankenhorn, B.S., 1 Kevin P. McMullen, M.D., 1,5 Mark A. Henderson M.D., 1 Edward J. Dropcho, M.D., 3 Mitesh V. Shah, M.D., 2, 4 Aaron A. Cohen-Gadol, M.D., M.Sc. 2, 4 1 Department of Radiation Oncology, 2 Department of Neurological Surgery, 3 Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 4 Goodman Campbell Brain and Spine, Indianapolis, IN 5 Indiana University Health Proton Therapy Center, Bloomington, IN Keywords: meningioma; atypical; radiation; proton therapy Corresponding author: Mark W. McDonald, MD Winship Cancer Institute of Emory University Department of Radiation Oncology 1365 Clifton Road NE, Suite A1300 Atlanta, GA 30322 Office: 404.778.3473 Fax: 404.778.4139 mark.mcdonald@emory.edu Dr. McDonald is now affiliated with the department of radiation oncology at Emory University. Dr. Henderson is now affiliated with the department of radiation oncology at Oregon Health and Science University. 1 Abstract We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n=12) or for recurrence or progression of residual tumor (n=10).
[Show full text]